Starpharma Clinical Trial Demonstrates Antitumour Efficacy Of DEP Irinotecan

Starpharma Holdings Ltd (ASX: SPL) has reported clinically significant results from its Phase 2 clinical trial of DEP irinotecan.

DEP irinotecan is a novel, patented nanoparticle formulation of SN381, the active metabolite of the widely used anti-cancer drug, irinotecan.

Developed using Starpharma’s proprietary DEP dendrimer technology, DEP irinotecan was designed to solubilise and directly deliver SN38 to cancer tissue.

Antitumour efficacy

The DEP irinotecan Phase 2 trial met its objectives, with endpoints demonstrating positive antitumour efficacy in multiple cancers.

The trial also confirmed the product’s favourable safety and tolerability profile.

Key efficacy results in heavily pre-treated patients with advanced colorectal cancer, 98% of whom experienced cancer progression following prior irinotecan treatment, include:

DEP irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin (LV) achieved median progression-free survival (mPFS) of 4.2 months, which is ~68% longer than published data on mPFS for conventional irinotecan plus 5-FU/LV as secondline therapy.

In these patients, the disease control rate (DCR) was 86%, and the objective response rate (ORR) was 14%, which also compares favourably to the published ORR of 4% for conventional irinotecan plus 5-FU/LV.

“Significant and sustained tumour shrinkage”

Dr Jia (Jenny) Liu MD PhD FRACP, Medical Oncologist and Principal Investigator at the Kinghorn Cancer Centre, St Vincent’s Hospital in Sydney, said: “The full DEP irinotecan / DEP SN38 trial results are very exciting.

“DEP irinotecan in heavily pretreated, advanced cancer patients demonstrated highly encouraging efficacy results in a range of tumour types.

“These responses include significant and sustained tumour shrinkage and disease control in patients with irinotecan-pre-treated colorectal cancer and platinum-resistant ovarian cancer.”

Liu noted that DEP irinotecan exhibits excellent tolerability, with a distinct lack of severe gastrointestinal toxicity that is a common and problematic feature of standard irinotecan treatment.

 

Disclaimer

JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest